tiprankstipranks
CymaBay collaboration in Japan further de-risks PBC data, says Piper Sandler
The Fly

CymaBay collaboration in Japan further de-risks PBC data, says Piper Sandler

After CymaBay Therapeutics announced that it has entered into a collaboration and license agreement with Kaken Pharmaceutical for the development and commercialization in Japan of seladelpar for the treatment of primary biliary cholangitis, or PBC, Piper Sandler analyst Yasmeen Rahimi argued that the collaboration "further de-risks" upcoming topline pivotal Phase 3 PBC data from the RESPONSE trial. The analyst, who says the deal highlights the value of this asset and contends that Japan is an important market for seladelpar given that there are currently no approved second line treatments for PBC in the country, has an Overweight rating and $12 price target on CymaBay shares.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on CBAY:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles